The European Medicines Agency (EMA) has published an artificial intelligence workplan to 2028, setting out new strategy on its use. The aim of this workplan to benefit public health through boosting the opportunities of artificial intelligence in different health fields.
In more detail
On 18 December 2023, the EMA published a workplan on Artificial Intelligence (AI) that includes a multitude of actions between 2023 and 2028. In this sense, the aim is to have a collaborative strategy to maximize the benefits of AI without falling into the risks that its use entails.
Taking into account the implications of AI in different areas of the healthcare sector, the EMA has focused its efforts on four dimensions that should contribute to improving the understanding and use of AI in a responsible way. The proposed workplan will be subject to future modifications as this technology evolves.
The key dimensions of the EMA workplan can be summarized as follows:
Through this workplan, the EMA takes a solid step forward in terms of integrating AI into its procedures and into the life cycle of medicinal products, which will undoubtedly be a milestone in terms of data collection and decision-making that may affect human health.
